Crispr Therapeutics AG Earnings
The next earnings date for Crispr Therapeutics AG is August 11, 2025.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of Crispr Therapeutics AG Earnings
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Crispr Therapeutics AG Earnings: Historical
More About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
“Crispr Therapeutics AG Earnings” Can Refer to the Crispr Therapeutics AG Earnings Date
Some people say “Crispr Therapeutics AG earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Crispr Therapeutics AG position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Crispr Therapeutics AG Stock on the Earnings Date
If you own Crispr Therapeutics AG stock (CRSP) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Crispr Therapeutics AG might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Crispr Therapeutics AG shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Owning Crispr Therapeutics AG Options on the Earnings Date
If you own Crispr Therapeutics AG options on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
In addition, the extrinsic values of Crispr Therapeutics AG options that overlap earnings dates are often higher than other days of the year. In other words, the premiums you pay to own Crispr Therapeutics AG options are typically higher during that period. In particular, they are frequently higher immediately before earnings and on the day they’re announced.
This makes sense considering that prices are often more volatile on earnings dates for Crispr Therapeutics AG. That potential volatility is a key factor that affects the premium cost of owning options.
Once the earnings announcement is done and the anticipated price volatility has gone down, the extrinsic values of Crispr Therapeutics AG options often go down. This is sometimes referred to as volatility crush.
Learning More Crispr Therapeutics AG Earnings
You can contact us any time if you would like to ask questions about Crispr Therapeutics AG earnings or anything else related to the stock market.